Search This Blog

Tuesday, June 2, 2026

Praxis pauses enrollment after Phase 2/3 in focal onset seizures misses primary endpoint

 


  • Company is pausing enrollment in the POWER2 trial to reassess the vormatrigine program following the POWER1 study results.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)